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A nthracyclines are highly effective and frequently used chemotherapy drugs (1) , with the most commonly used being doxorubicin, alone or in combination with other anticancer agents.
A prominent undesired effect of anthracycline therapy is cardiotoxicity and subsequent heart failure; depending on the accumulated dose, the incidence of severe anthracycline-induced cardiotoxicity resulting in overt systolic heart failure can be as high as 25% (2) . The trade-off between cancer and chronic heart failure places an immense personal burden on patients, with physical and psychological consequences.
Anthracyclines bind to topoisomerase 2b in the cardiomyocyte's DNA. Anthracyclinestopoisomerase 2b complexes bind to promoters of mitochondrial antioxidative, biogenesis, and electron transport chain genes leading to a downstream mitochondrial dysfunction. In fact, genetic ablation of topoisomerase 2b in mice ameliorates anthracycline-induced cardiotoxicity (3) . In addition, anthracyclines bind to cardiolipin in the inner mitochondrial membrane, contributing to increased reactive oxygen species generation, iron deposition, and defective mitochondrial biogenesis (3, 4) . Altogether, these phenomena lead to mitochondrial swelling, intracardiomyocyte vacuolization, and ultimately, cell death and replacement of cardiomyocytes by fibrotic tissue (5) (6) (7) .
Current algorithms to identify early stages of anthracycline-induced cardiotoxicity are far from optimal. Diagnosis generally occurs once left ventricular (LV) functional deterioration becomes manifest, either as a decline in left ventricular ejection fraction (LVEF) or longitudinal LV strain abnormalities (8, 9) . By this stage, the damage to the myocardium is often irreversible. The lack of a validated early damage marker limits the development of preventive strategies. Cardiac magnetic resonance (CMR)
is the gold standard technique for anatomical and functional evaluation of the heart, and the advent of multiparametric algorithms allows accurate characterization of myocardial tissue. CMR is thus suitable for the detection of myocardial edema (10) (11) (12) and diffuse myocardial fibrosis (13) (14) (15) , which are present at different stages of anthracycline-induced cardiotoxicity (16) (17) (18) (19) (20) (21) . To date, there has been a lack of comprehensive serial multiparametric CMR tissue studies characterizing the full anthracycline treatment cycle from pre-treatment, through treatment, to overt LV systolic dysfunction and heart failure.
Here, we used a large animal model (pig) of doxorubicin-induced cardiotoxicity to identify the earliest CMR marker of myocardial damage and its pathological correlates. We also studied the reversibility of cardiotoxicity upon detection of the early CMR marker.
METHODS STUDY DESIGN. The study was approved by the Institutional Animal Research Committee and conducted in accordance with recommendations of the Guide for the Care and Use of Laboratory Animals.
The study design is summarized in Figure 1 . Galán-Arriola et al. Large white castrated male pigs weighing 25 to 30 kg were used in this study. Animals were divided into 4 experimental groups of 5 animals each. Group 1 animals received 5 biweekly intracoronary (IC) doxorubicin (doxo) doses followed by 8 dose-free weeks, whereas Group 2 pigs received 3 biweekly IC doxo doses followed by 12 dose-free weeks. Group 3 pigs received 3 IC doxo dose followed by 2 dose-free weeks before sacrifice. Group 4 was a control group of untreated animals. Cardiac magnetic resonance scans were performed every week in each group, before doxo infusion. Infused and remote myocardial areas were collected at sacrifice for further analysis. Galán-Arriola et al. Table 1 . In agreement with the LVEF data, no regional contractile abnormalities were documented until week 12, when the doxorubicin-infused myocardium showed regional wall motion defects (data not shown). Table 1 . Previous CMR evaluations of anthracyclineinduced cardiotoxicity have been performed in mice (26) , rats (27, 28) , and rabbits (29, 30) ; however, ours is the first study to use the pig model with serial CMR evaluations. We chose the pig because of its anatomical and physiological similarity to humans Galán-Arriola et al.
F E B R U A R Y 2 6 , 2 0 1 9 : 7 7 9 -9 1 T2 Mapping CMR and Anthracycline Cardiotoxicity T 2 mapping is an accurate technique for the detection and quantification of myocardial edema (10) . We have previously used T 2 mapping to characterize the edematous reaction of porcine (11, 25, 33) and human (12) Serial multiparametric cardiac magnetic resonance (CMR) might serve to implement a personalized treatment approach for patients undergoing anthracycline therapy to prevent cardiotoxicity.
Galán-Arriola et al. that result in significant myelosuppression and compromise the experimental setting (42) . The intracoronary approach in the pig model was described by Christiansen et al. (23) and has been validated by several imaging approaches as a valid alternative. In this study, all animals showed a very similar behavior in terms of time to intracardiomyocyte edema and time to LVEF fall. In the clinical setting, this is expected to be more variable.
In addition, the time window between T 2 relaxation time prolongation and LVEF fall (3 weeks) appears narrow to be picked-up in the clinical setting. We speculate that this time window might be significantly wider in patients due to the more concealed evolution of the disease but this is to be demonstrated in the clinics. T2 Mapping CMR and Anthracycline Cardiotoxicity F E B R U A R Y 2 6 , 2 0 1 9 : 7 7 9 -9 1
